Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + dihydroxyaluminum aminoacetate + heavy magnesium carbonate
- Development stage
- Unknown
- Lead developer
- Lion Corporation
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aspirin + dihydroxyaluminum aminoacetate + heavy magnesium carbonate is a buffered formulation of aspirin (acetylsalicylic acid) designed to provide antiplatelet and anti-inflammatory effects while minimizing gastrointestinal side effects. Aspirin acts by irreversibly acetylating the active site of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby inhibiting the production of thromboxane A2 in platelets and prostaglandins in various tissues. The inclusion of dihydroxyaluminum aminoacetate (aluminum glycinate) and heavy magnesium carbonate serves as a buffering system that neutralizes gastric acid and protects the stomach lining from the direct and indirect irritant effects of aspirin. This combination is widely used for the secondary prevention of cardiovascular events such as myocardial infarction and angina pectoris, the management of ischemic cerebrovascular disorders, and the treatment of Kawasaki disease. It is particularly prevalent in Asian markets, where it is often marketed under the brand name Bufferin.
- Brand names
- Bufferin
- Other names
- Buffered aspirinAspirin/Dihydroxyaluminum aminoacetate/Magnesium carbonate
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on aspirin + dihydroxyaluminum aminoacetate + heavy magnesium carbonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + dihydroxyaluminum aminoacetate + heavy magnesium carbonate.